--- title: "What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday?" type: "News" locale: "en" url: "https://longbridge.com/en/news/275766559.md" description: "Phio Pharmaceuticals Corp. (NASDAQ:PHIO) stock fell 4.65% to $1.23 on Thursday after a nearly 15% rally, despite positive Phase 1b trial results showing an 85% response rate for its lead candidate, PH-762. Analysts maintain Buy ratings with an average price target of $10.67. The stock is trading near 52-week lows, with mixed technical indicators suggesting a neutral to bullish momentum. The company plans to submit for FDA guidance on PH-762 in Q2 2026 and commence manufacturing by the second half of 2026." datetime: "2026-02-12T13:43:54.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275766559.md) - [en](https://longbridge.com/en/news/275766559.md) - [zh-HK](https://longbridge.com/zh-HK/news/275766559.md) --- # What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday? **Phio Pharmaceuticals Corp**. (NASDAQ:PHIO) stock is trading lower on Thursday; however, there is no news to justify the movement. The stock could possibly be down on profit-taking after the stock closed nearly 15% higher on Wednesday. On Tuesday, the company shared positive results from its Phase 1b clinical trial for its lead candidate, PH-762. ## PH-762 Shows 85% Pathological Response Rate Phio Pharmaceuticals’ lead clinical program is **PH-762** (often referred to in the context of their INTASYL platform), which is an investigational, self-delivering RNAi compound designed to treat skin cancers. It works by silencing the PD-1 gene to enhance the immune system’s ability to kill tumor cells. Phio Pharmaceuticals recently announced positive results from its Phase 1b clinical trial for its lead candidate, PH-762, which showed an 85% pathological response rate at the highest dose concentration. The trial involved 22 patients with cutaneous carcinomas, and the Safety Monitoring Committee reported no serious adverse events, indicating a promising outlook for the drug. The company is targeting an FDA submission for guidance on clinical study design for PH-762 in the second quarter of 2026, with plans to commence manufacturing of cGMP material by the second half of 2026. These developments highlight the potential of PH-762 as a non-surgical treatment for skin cancers. ## PHIO Mixed Technical Indicators The stock is currently trading 18.4% above its 20-day simple moving average (SMA) but is 18.3% below its 100-day SMA, indicating mixed signals in the short to medium term. Over the past 12 months, shares have decreased by approximately 29.51% and are currently positioned closer to their 52-week lows than highs. The RSI is at 66.61, which is considered neutral territory, while the MACD is above its signal line, indicating bullish momentum. The combination of neutral RSI and bullish MACD suggests mixed momentum for the stock. - **Key Resistance**: $1.50 - **Key Support**: N/A **Analyst Consensus & Recent Actions:** The stock carries a **Buy** Rating with an average price target of **$10.67**. Recent analyst moves include: - **HC Wainwright & Co.**: Buy (Maintains Target to $14.00) (Feb. 10) **PHIO Price Action:** Phio Pharma shares were down 4.65% at $1.23 during premarket trading on Thursday, according to Benzinga Pro data. _Photo by Aunt Spray via Shutterstock_ ### Related Stocks - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [PHIO.US](https://longbridge.com/en/quote/PHIO.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) ## Related News & Research - [BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug](https://longbridge.com/en/news/282702171.md) - [Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026 | PHIO Stock News](https://longbridge.com/en/news/282184588.md) - [Replimune Disputes FDA Rejection of Skin Cancer Treatment, Criticizes Review Process](https://longbridge.com/en/news/282393660.md) - [FDA Again Rejects Replimune Skin Cancer Therapy, Says Evidence Falls Short](https://longbridge.com/en/news/282376421.md) - [Pancreatic cancer pill shown to nearly double overall survival time, drug company says](https://longbridge.com/en/news/282687539.md)